10115590LNP-mRNA Vaccine Patch In Vivo Immunisation StudyClosedCollaborative R&DInnovate UKMNS is at the forefront of revolutionising vaccine delivery through our groundbreaking mRNA vaccine patch immunogenicity project. Our endeavour focuses on developing innovative vaccine patches, as a pioneering needle free approach set to transform traditional vaccine administration methods. Our project is driven by the need for more efficient and accessible vaccine delivery systems, particularly in response to challenges witnessed during the COVID-19 pandemic. Recognising the limitations of existing vaccine distribution and storage methods, particularly in low and middle-income countries, MNS is dedicated to creating a solution that is not only effective but also environmentally sustainable and culturally sensitive. The core of our innovation lies in the development of immunogenic mRNA vaccine patches. These patches represent a significant advancement over traditional needle-based vaccinations. They are designed to be thermally stable, eliminating the need for cold chain logistics, which is a major hurdle in vaccine distribution. This feature makes our vaccine patches particularly suitable for regions with limited healthcare infrastructure. Another key aspect of our project is the non-invasive nature of the vaccine patches. They are painless and easy to administer, supporting increased vaccine uptake and compliance, especially among populations with needle phobia. The simple administration could also allow for self-application, further enhancing access to vaccinations. Environmentally, our mRNA vaccine patches are a sustainable option as they significantly reduce biomedical waste associated with syringes and needles and minimise the carbon footprint linked to traditional vaccine distribution methods. MNS are motivated by social responsibility aimed at addressing global health disparities. By simplifying vaccine administration and making it more accessible, we aim to contribute significantly to global health challenges, especially in regions where healthcare resources are scarce. Our vision is fuelled by the belief that everyone, regardless of where they live, should have access to life-saving vaccines. The MNS mRNA vaccine patch that will be developed in this project is a step towards a healthier, more equitable world, where barriers to healthcare are minimised, and the well-being of communities is prioritised. This project, upon successful development and deployment, has the potential to make a lasting impact on global vaccine delivery and public health.